|
|
|||
|
|||
|
|
|||
|
milk protein allergy |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
milk protein allergy DESCRIPTION Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist(LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide milk protein allergy. The molecular weight of zafirlukast is 575.7 and the structural formula is:
Zafirlukast, a fine white to pale yellow amorphous powder, is practically insolublein water milk protein allergy. It is slightly soluble in methanol and freely soluble in tetrahydrofuran,dimethylsulfoxide, and acetone milk protein allergy. ACCOLATE is supplied as 10 and 20 mg tablets for oral administration milk protein allergy. Inactive Ingredients: Film-coated tablets containing croscarmellose sodium,lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose,and titanium dioxide milk protein allergy.
In vitro studies demonstrated that zafirlukast antagonized the contractileactivity of three leukotrienes (LTC 4 , LTD 4 and LTE 4 ) in conducting airwaysmooth muscle from laboratory animals and humans milk protein allergy. Zafirlukast prevented intradermalLTD 4 -induced increases in cutaneous vascular permeability and inhibited inhaledLTD 4 -induced influx of eosinophils into animal lungs milk protein allergy. Inhalational challengestudies in sensitized sheep showed that zafirlukast suppressed the airway responsesto antigen; this included both the early- and late-phase response and the nonspecifichyperresponsiveness milk protein allergy. In humans, zafirlukast inhibited bronchoconstriction caused by several kindsof inhalational challenges milk protein allergy. Pretreatment with single oral doses of zafirlukastinhibited the bronchoconstriction caused by sulfur dioxide and cold air in patientswith asthma milk protein allergy. Pretreatment with single doses of zafirlukast attenuated the early-and late-phase reaction caused by inhalation of various antigens such as grass,cat dander, ragweed, and mixed antigens in patients with asthma milk protein allergy. Zafirlukastalso attenuated the increase in bronchial hyperresponsiveness to inhaled histaminethat followed inhaled allergen challenge milk protein allergy. Clinical Pharmacokinetics and Bioavailability: Distribution Metabolism Excretion In the pivotal bioequivalence study, the mean terminal half-life of zafirlukastis approximately 10 hours in both normal adult subjects and patients with asthma milk protein allergy. In other studies, the mean plasma half-life of zafirlukast ranged from approximately8 to 16 hours in both normal subjects and patients with asthma milk protein allergy. The pharmacokineticsof zafirlukast are approximately linear over the range from 5 mg to 80 mg milk protein allergy. Steady-stateplasma concentrations of zafirlukast are proportional to the dose and predictablefrom single-dose pharmacokinetic data milk protein allergy. Accumulation of zafirlukast in the plasmafollowing twice-daily dosing is approximately 45% milk protein allergy. The pharmacokinetic parameters of zafirlukast 20 mg administered as a singledose to 36 male volunteers are shown with the table below milk protein allergy. Mean (% Coefficient of Variation) pharmacokinetic
Race: No differences in the pharmacokinetics of zafirlukast due to race havebeen observed milk protein allergy. Elderly: The apparent oral clearance of zafirlukast decreases with age milk protein allergy. Inpatients above 65 years of age, there is an approximately 2-3 fold greater Cmax and AUC compared to young adult patients milk protein allergy. Children: Following administration of a single 20 mg dose of zafirlukast to20 boys and girls between 7 and 11 years of age, and in a second study, to 29boys and girls between 5 and 6 years of age, the following pharmacokinetic parameterswere obtained: Parameter Children age
Zafirlukast disposition was unchanged after multiple dosing (20 mg twice daily)in children and the degree of accumulation in plasma was similar to that observedin adults milk protein allergy. Hepatic Insufficiency: In a study of patients with hepatic impairment (biopsy-provencirrhosis), there was a reduced clearance of zafirlukast resulting in a 50-60%greater C max and AUC compared to normal subjects milk protein allergy. Renal Insufficiency: Based on a cross-study comparison, there are no apparentdifferences in the pharmacokinetics of zafirlukast between renally-impairedpatients and normal subjects milk protein allergy. Drug-Drug Interactions
|
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| mmilk protein allergy miilk protein allergy millk protein allergy milkk protein allergy milk protein allergy milk pprotein allergy milk prrotein allergy milk prootein allergy milk prottein allergy milk proteein allergy milk proteiin allergy milk proteinn allergy milk protein allergy milk protein aallergy milk protein alllergy milk protein alllergy milk protein alleergy milk protein allerrgy milk protein allerggy milk protein allergyy ilk protein allergy mlk protein allergy mik protein allergy mil protein allergy milkprotein allergy milk rotein allergy milk potein allergy milk prtein allergy milk proein allergy milk protin allergy milk proten allergy milk protei allergy milk proteinallergy milk protein llergy milk protein alergy milk protein alergy milk protein allrgy milk protein allegy milk protein allery milk protein allerg m ilk protein allergy mi lk protein allergy mil k protein allergy milk protein allergy milk protein allergy milk p rotein allergy milk pr otein allergy milk pro tein allergy milk prot ein allergy milk prote in allergy milk protei n allergy milk protein allergy milk protein allergy milk protein a llergy milk protein al lergy milk protein all ergy milk protein alle rgy milk protein aller gy milk protein allerg y milk protein allergy imlk protein allergy mlik protein allergy mikl protein allergy mil kprotein allergy milkp rotein allergy milk rpotein allergy milk portein allergy milk prtoein allergy milk proetin allergy milk protien allergy milk proteni allergy milk protei nallergy milk proteina llergy milk protein lalergy milk protein allergy milk protein alelrgy milk protein allregy milk protein allegry milk protein alleryg amilk protein allergy themilk protein allergy milk protein allergy | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
